BIOA vs INCY · rev $9.0M vs P/E 14, rev $5.14B
BioAge Labs, Inc (BIOA) versus Incyte Corporation (INCY) — a side-by-side from cached financials, not a winner call.
BioAge Labs, Inc (BIOA) is a drug manufacturers - specialty & generic company listed on US.
Incyte Corporation (INCY) is a biotechnology company listed on US.
Latest reported BIOA revenue for 2025-12-31 was $9.0M. Net income was -$80.6M. BIOA currently screens at market cap $697.9M.
Latest reported INCY revenue for 2025-12-31 was $5.14B. Net income was $1.29B. Revenue was up 21.2% from 2024-12-31 to 2025-12-31. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
BIOA currently screens at market cap $697.9M. INCY currently screens at market cap $20.45B and trailing P/E 14.5.
Not investment advice. Open the BIOA and INCY stock pages for the full models.
Not investment advice.